期刊文献+

扶正化瘀方联合化疗辩治胃癌患者的研究 被引量:2

下载PDF
导出
摘要 目的探讨扶正化瘀方联合化疗辩治胃癌患者的临床效果。方法选取我科在2016年6月至2017年5月期间诊治的66例胃癌患者作为研究对象,按照随机的原则平均分成对照组和观察组,对照组采用单纯化疗治疗,观察组在对照组的基础上增加扶正化瘀方辩证治疗。结果观察组治疗的有效率为69.70%,明显高于对照组的39.40%,两组对比差异具有统计学意义(P<0.05);治疗前两组患者免疫功能相关指标相比无显著差异,治疗后两组患者的免疫功能指标都有所改善,且观察组改善更加明显,与对照组相比差异具有统计学意义(P<0.05)。结论对胃癌患者联合采用化疗和扶正化瘀方辩证治疗,效果显著,值得临床推广。
作者 张美艳
出处 《中国医药指南》 2018年第29期179-180,共2页 Guide of China Medicine
  • 相关文献

参考文献5

二级参考文献64

  • 1Lordick F, Allum W, Carneiro F, et al. Urunet needs and challenges in gastric cancer: the way Iorward[J]. Cancer Treat Rev, 2014, 40 (6) :692-700.
  • 2Bang XJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in eambination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialill. Lancet, 2010, 376(9742):687-697.
  • 3Cradishar W], Tjulandin S, Davidson N, et al. Phase ill trial of nanoparticle albumin- bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancerill.] Clin Oneal, 2005, 23(31):7794-7803.
  • 4Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab- paclitaxel plus gemcitabine[J]. N Engl] Med, 2013, 369(18):1691-1703.
  • 5Sasaki Y, Nishina T, Yasui H, et al. Phase II trial of nanoparticle albumin- bound paclitaxel as second- line chemotherapy for unresectable or recurrent gastric cancer[J], Cancer Sci, 2014, 105(7): 812-817.
  • 6Yardley DA. nab-Paclitaxel mechanisms of action and delivery[J], J Control Release, 2013, 170(3) :365-372.
  • 7Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular differentiation and tissue response to injuryill.] Clin Invest, 2001, 107(9):1049-1054.
  • 8Bomstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function[J]. Curr Opin Cell Bioi, 2002, 14(5) :608-616.
  • 9Zhao ZS, Wang YY, Chu YQ, et al. SPARC is associated with gastric cancer progression and poor survival of patiems[J]. Clin Cancer Res, 2010, 16(1):260-268.
  • 10]eung HC, Rha SY, Im CK, et al. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy[J], Cancer, 2011,117(10):2050-2057.

共引文献90

同被引文献28

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部